Atia Vision Company Profile

Background

Atia Vision, Inc., founded in 2012 and headquartered in Campbell, California, is a medical device company specializing in the development of innovative intraocular lenses (IOLs) aimed at restoring dynamic vision for patients undergoing cataract surgery. The company's mission is to enhance patient outcomes by addressing the limitations of existing presbyopia-correcting lenses through advanced technological solutions.

Key Strategic Focus

Atia Vision's primary strategic objective is to revolutionize cataract treatment by introducing the OmniVu™ Lens System, a modular, shape-changing IOL designed to provide a continuous range of vision from near to far distances. This dual-optic system leverages the eye's natural accommodative mechanism, aiming to deliver superior visual outcomes without the common visual disturbances associated with traditional lenses.

Financials and Funding

Since its inception, Atia Vision has successfully secured substantial funding to support its research and development initiatives:

Series A (2013): Raised $1.11 million.

Series B (2015): Secured $5 million.

Series C (2017-2018): Conducted two rounds, raising undisclosed amounts.

Series D (2019): Closed a $20 million financing round, led by Cormorant Asset Management, with participation from The Capital Partnership (TCP), AMED Ventures, and Shangbay Capital.

Series E (2022): Raised $42 million, led by Cormorant Asset Management, with contributions from TCP, PA MedTech VC Fund, AMED Ventures, and Shifamed angel investors.

The capital raised has been allocated towards advancing clinical programs, scaling manufacturing capabilities, and expanding the team to support the development and commercialization of the OmniVu™ Lens System.

Pipeline Development

The OmniVu™ Lens System is Atia Vision's flagship product, currently progressing through various stages of clinical evaluation:

International Trials: Over 75 lenses have been implanted in first-in-human and feasibility studies, with follow-ups extending up to three years. Results demonstrated a continuous range of focus from far to near, with 100% of patients achieving 20/20 or better uncorrected distance vision.

FDA Approval (2025): Received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to commence a traditional feasibility clinical study in the United States.

Technological Platform and Innovation

Atia Vision's OmniVu™ Lens System distinguishes itself through several proprietary technologies and innovative methodologies:

Dual-Optic Design: Comprises a fluid-filled, shape-changing base that provides focusing capability and a front optic that docks into the base to deliver optical power. This design aims to preserve the eye's anatomical integrity and elasticity.

Natural Accommodation: The lens system is engineered to mimic the eye's natural focusing ability, offering a more physiologic visual experience across all distances without generating side effects such as halos or glare.

Leadership Team

Atia Vision's leadership comprises experienced professionals dedicated to advancing ophthalmic medical devices:

Mariam Maghribi, Ph.D. – President and Chief Executive Officer: Leads the company's strategic direction and operations.

Claudio Argento, Ph.D. – Co-Founder and Chief Technology Officer: Oversees technological development and innovation.

David Voris – Chief Financial Officer: Manages financial strategy and operations.

Amr Salahieh – Co-Founder and Chairman: Provides strategic guidance and oversight.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within Atia Vision's leadership team.

Competitor Profile

Market Insights and Dynamics

The global intraocular lens market is experiencing significant growth, driven by an aging population and increasing prevalence of cataracts. Traditional monofocal lenses dominate the market; however, there is a growing demand for advanced presbyopia-correcting lenses that offer a full range of vision without compromising quality.

Competitor Analysis

Key competitors in the presbyopia-correcting IOL market include:

Alcon: Offers multifocal and extended depth of focus IOLs.

Johnson & Johnson Vision: Provides a range of IOLs, including the TECNIS series.

Bausch + Lomb: Develops various IOLs catering to different patient needs.

These companies focus on enhancing visual outcomes through innovative lens designs and technologies.

Strategic Collaborations and Partnerships

Atia Vision is a portfolio company of Shifamed LLC, a Silicon Valley-based medical innovation hub. This affiliation provides access to a network of resources, expertise, and support, facilitating the development and commercialization of the OmniVu™ Lens System.

Operational Insights

Atia Vision's strategic considerations include:

Technological Differentiation: The OmniVu™ Lens System's unique dual-optic design and natural accommodation capabilities set it apart from existing solutions.

Clinical Validation: Positive outcomes from international trials and FDA approval for U.S. studies bolster the company's credibility and market position.